+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-10-14Number of Pages: 111

Fragment-based Drug Discovery Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Fragment-based Drug Discovery Market: Snapshot

The introduction of new techniques into the existing fragment-based drug discovery practices have created significant reductions in time and cost, driving the demand for such practices. Combinational chemistry and high-throughput screening are some of the more recently introduced practices that have helped make fragment-based drug discovery programs a lot faster and cheaper than before. 

Additionally, as the usage of fragment-based drug discovery grows in the field of discovering weaker inhibitors, biophysical techniques become extremely useful. These techniques can be used to measure binding within fragment compounds that possess low affinity for binding.

The demand for fragment-based drug discovery, however, is expected to be greatly hindered by the lowered potency of fragment screening, the most popular component, in certain compounds. The drugs generated have a lower than required potency, thus deterring several end users from approaching this technique.

The collective impact of all such drivers and restraints can be seen on the global fragment-based drug discovery market, which is expected to expand at a CAGR of 14.4% from 2015 to 2023 by revenue. By the end of 2016, this revenue is expected to reach US$435.6 mn and US$1.15 bn by the end of 2023.

North America Expected to Continue Leading Demand for Fragment-based Drug Discovery Programs

By the end of 2023, the market value of fragment-based drug discovery techniques in North America is expected to be 45.4% of the global market. While this is a drop in market value from its 2014 statistic, North America will still enjoy being a leading geographical segment for advancements in fragment-based drug discovery techniques.

The key factors responsible for the leading role of North America in fragment-based drug discovery programs is the high rate of research and development efforts undertaken by prominent market players in the region. The U.S. and Canada are both countries with advanced healthcare systems and infrastructures, and are often the base of advanced technological implementations, making North America the hub for the latest developments in fragment-based drug discovery.

This region is also ramping up its speed in development of fragment-based drug discovery techniques by employing outsourcing facilities from Asia Pacific. The demand for fragment-based drug discovery in Asia Pacific, on the other hand, is a lot higher than any other major region, owing to the rapid improvements in healthcare infrastructure and focus on better quality management in countries such as Japan and China.

Biopharmaceutical Companies Top the List of Fragment-based Drug Discovery Demand

Fragment-based drug discovery techniques have grown significantly in popularity in the recent years and have found a great scope of use in the biopharmaceuticals. This includes large companies, academic bodies, and CROs. These techniques have helped massively in creating chemical series that possess lead-like properties as they have improved the success rate of creation significantly over the conventional screening methods. Fragment-based drug discovery techniques have also been extremely useful in marking out chemical motifs from multiple targets.

It is a combination of all these factors that are expected to drive the use of fragment-based drug discovery in biopharmaceutical facilities to a revenue generation of US$565.2 mn by the end of 2023. The key providers of fragment-based drug discovery programs include Astex Pharmaceuticals, Charles River Laboratories International, Inc., Sygnature Discovery, Evotec A.G., and Beactica AB.


Chapter 1 Preface 
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology 
1.4 Research Methodology: Assumptions 

Chapter 2 Executive Summary 
2.1 Global Fragment-based Drug Discovery Market, Estimates and Forecast, By Revenue, 2013–2023 (US$ Mn) 
2.2 Global Fragment-based Drug Discovery Market Revenue, by Services, 2014 (US$ Mn) 
2.3 Global Fragment-based Drug Discovery Market Revenue, by End-user, 2014 (US$ Mn) 
2.4 Global Market Share, by Geography, 2014 and 2023 (Value %) 
2.5 Fragment-based Drug Discovery Market Snapshot 

Chapter 3 Fragment-based Drug Discovery Market Overview 
3.1 Introduction 
      3.1.1 Hit to Lead  
      3.1.2 Progression to Candidates from Fragment Leads 
3.2 Event Impact Analysis 
3.3 Future Trends and Developments 
3.4 Market Drivers 
      3.4.1 Simpler and less time consuming technique 
      3.4.2 Streamlining and easy access to advanced biophysical techniques
3.5 Restraints 
      3.5.1 Lower level of potency in few of the compounds derived from fragment screening  
      3.5.2 Requirement of high protein and unique fragment library for conducting studies 
3.6 Opportunities 
      3.6.1 Merging of computational biology with biophysical techniques 
      3.6.2 Emerging economies to offer sustained growth opportunities 
3.7 Porter’s Five Forces Analysis 
3.8 Recent Developments in Fragment-based Drug Discovery 
3.9 Fragment-based Drug Discovery: Case Histories 
3.10 Market Share – Fragment-based Drug Discovery Market (2014) (%)  
3.11 Market Attractiveness Analysis – Fragment-based Drug Discovery Market 

Chapter 4 Market Segmentation – By Services Component 
4.1 Introduction 
4.2 Comparative Analysis of FBDD and HTS 
4.3 Global Fragment Screening Market Revenue for FBDD, 2013 – 2023 (US$ Mn) 
      4.3.1 Global Biophysical Techniques Market for FBDD (US$ Mn), 2013 – 2023) 
             4.3.1.1 Global NMR Spectroscopy Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.2 Global DSF Assay Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.3 Global Fluorescence Polarization (FP) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.4 Global Isothermal Titration Calorimetry (ITC) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.5 Global X-ray Crystallography Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.6 Global SPR Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.7 Global Biolayer Interferometry Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.8 Global Mass Spectrometry (MS) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.9 Global Capillary Electrophoresis (CE) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
             4.3.1.10 Global Other (Biochemical Assays) Market Revenue for FBDD, 2013–2023 (US$ Mn) 
      4.3.2 Global Non-biophysical Techniques Market Revenue for FBDD, 2013–2023 (US$ Mn) 
4.4 Global Fragment Optimization Market Revenue for FBDD, 2013–2023 (US$ Mn) 

Chapter 5 Market Segmentation – By End-user 
5.1 Introduction 
5.2 Global Market for Fragment-based Drug Discovery in Biopharmaceutical Companies, 2013–2023 (US$ Mn) 
5.3 Global Market for Fragment-based Drug Discovery in CROs, 2013–2023 (US$ Mn) 
5.4 Global Market for Fragment-based Drug Discovery in Academic and Research Institutions, 2013–2023 (US$ Mn) 

Chapter 6 Fragment-based Drug Discovery Market - Regional Analysis 
6.1 Global Overview 
6.2 North America Fragment-based Drug Discovery Market Overview 
      6.2.1 U.S. Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.2.2 Canada Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
6.3 Europe Fragment-based Drug Discovery Market Overview 
      6.3.1 Germany Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.3.2 U.K. Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
      6.3.3 Rest of Europe Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
6.4 Asia Pacific Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
      6.4.1 Japan Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.4.2 Australia Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
      6.4.3 Rest of Asia Pacific Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
6.5 LATAM Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 
      6.5.1 Brazil Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 
      6.5.2 Rest of LATAM Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 
6.6 RoW Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 

Chapter 7 Company Profiles 
7.1 Astex Pharmaceuticals 
7.2 Alveus Pharmaceuticals Pvt. Ltd. 
7.3 Beactica AB 
7.4 Charles River Laboratories International, Inc. 
7.5 Crown Bioscience, Inc. 
7.6 Emerald BioStructures, Inc. 
7.7 Evotec AG 
7.8 Kinetic Discovery Limited
7.9 Proteros Fragments GmbH 
7.10 Sprint Bioscience 
7.11 Structure Based Design, Inc.  
7.12 Sygnature Discovery 

The increasing search for new drugs to treat complicated medical problems has led to a surge in the global fragment-based drug discovery market. Furthermore, the growth of the global fragment-based drug discovery market has also led to dominance of biopharmaceutical companies, as the market requires a system for identification of lead compounds in the process of drug discovery. 

The report published by Transparency Market Research on the global fragment-based drug discovery market gives a comprehensive overview of the important dynamics and trends. The report assesses the threat from new entrants, threat of substitute products or services, bargaining power of customers, bargaining power of suppliers, and the intensity of competitive rivalry with the help of a Porter’s five forces analysis. Furthermore, it also evaluates the strengths, weaknesses, opportunities, and threats of the market with the help of a SWOT analysis. The report gives a clear understanding of the competitive landscape and segmentation of the market and an overview of the global fragment-based drug discovery market to enable its readers to make well-informed business decisions.

Overview of Global Fragment-Based Drug Discovery Market

The drivers for the global fragment-based drug discovery market are its time-saving attributes and quick access to biophysical fragment screening techniques. Fragment-based drug discovery has become a method of designing unique molecules. This technique uses smaller ‘fragments or ligands’, which have lower molecular weights. The main restraint on the global fragment-based drug discovery market is the weak potency of a few compounds that are derived from fragment screening. The other conspicuous restraint on this market is the need for special ‘fragment libraries’ for conducting research.

The global fragment-based drug discovery market has been segmented into fragment screening and fragment optimization. The fragment screening segment is further sub-segmented into biophysical techniques and non-biophysical techniques. Biophysical techniques include isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR) spectroscopy, fluorescence polarization (FP), differential scanning fluorimetry (DSF), surface plasmon resonance, X-ray crystallography, assay (thermal shift), biolayer interferometry, capillary electrophoresis, mass spectrometry, and others (biochemical assays). The end-use applications encouraging the growth of this market are CROs, biopharmaceutical companies, and academic and research institutions. Geographically, the global fragment-based drug discovery market is divided into regions such as North America, Asia Pacific, Europe, Latin America, and Rest of the World.

North America dominated the global fragment-based drug discovery market due to growing awareness about this sector and the high level of its adoption by pharmaceutical companies. However, in the coming years, the Asia Pacific fragment-based drug discovery market will witness phenomenal growth due to the growing number of research and development activities. 

Companies Mentioned in the Global Fragment-Based Drug Discovery Market Report 

The important players in the global fragment-based drug discovery market are Astex Pharmaceuticals, Beactica AB, Structure Based Design, Inc., Alveus Pharmaceuticals Pvt. Ltd., Emerald BioStructures, Inc., Evotec AG, Crown Bioscience, Inc., Kinetic Discovery Limited, Sprint Bioscience, Proteros Fragments GmbH, Charles River Laboratories International, Inc., and Sygnature Discovery.

The global fragment-based drug discovery market has been segmented as follows:

Fragment-Based Drug Discovery Market, by Services Component

  • Fragment Screening
    • Biophysical Techniques
      • Nuclear Magnetic Resonance (NMR) Spectroscopy
      • Differential scanning Fluorimetry (DSF) Assay (Thermal Shift)
      • Fluorescence Polarization (FP)
      • Isothermal Titration Calorimetry (ITC)
      • X-ray Crystallography
      • Surface Plasmon Resonance
      • Biolayer Interferometry
      • Mass Spectrometry
      • Capillary Electrophoresis
      • Others (Biochemical Assays)
    • Non-biophysical Techniques
  • Fragment Optimization

Fragment-Based Drug Discovery Market, by End-user

  • Biopharmaceutical Companies
  • CROs
  • Academic and Research Institutions

Fragment-Based Drug Discovery Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific (APAC)
    • Australia
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Rest of the World (RoW)

This report gives you access to decisive data such as:

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top